Kythera Biopharmaceuticals Inc Quick Ratio (KYTH) starting from the second quarter 2015 to second quarter 2014, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kythera Biopharmaceuticals Inc  (KYTH)

Kythera Biopharmaceuticals Inc's Quick Ratio

KYTH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2015, Quick Ratio fell to 7.81 above Kythera Biopharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Quick Ratio than Kythera Biopharmaceuticals Inc in second quarter 2015. While Quick Ratio total ranking has improved so far during the Q2 2015 to 404, from total ranking in the first quarter 2015 at 472.

Explain Quick Ratio?
How much Cash & cash equivalents KYTH´s has?
What are KYTH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KYTH Quick Ratio (Jun 30 2015)
Q2		 (Mar 31 2015)
Q1		 (Dec 31 2014)
Q4		 (Sep 30 2014)
Q3		 (Jun 30 2014)
Q2
Y / Y Current Liabilities Change 69.4 % 43.08 % 17.34 % -13.84 % -35.6 %
Y / Y Cash & cash equivalent Change 37.25 % 38.73 % -42.1 % 84.3 % 77.98 %
Quick Ratio MRQ 7.81 10.83 4.83 6.74 9.64
KYTH's Total Ranking # 404 # 472 # 472 # 441 # 327
Seq. Current Liabilities Change 21.21 % -5.3 % 18.4 % 24.65 % 2.37 %
Seq. Cash & cash equivalent Change -12.67 % 112.39 % -15.14 % -12.8 % -11.72 %



Quick Ratio second quarter 2015 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 189
Overall Market # 404


Quick Ratio Statistics
High Average Low
11.17 6.76 3.13
(Mar 31 2014)   (Sep 30 2012)




Financial Statements
Kythera Biopharmaceuticals Inc's Current Liabilities $ 24 Millions Visit KYTH's Balance sheet
Kythera Biopharmaceuticals Inc's Cash & cash equivalent $ 185 Millions Visit KYTH's Balance sheet
Source of KYTH's Sales Visit KYTH's Sales by Geography


Cumulative Kythera Biopharmaceuticals Inc's Quick Ratio

KYTH's Quick Ratio for the trailling 12 Months

KYTH Quick Ratio

 (Jun 30 2015)
12 Months		 (Mar 31 2015)
12 Months		 (Dec 31 2014)
12 Months		 (Sep 30 2014)
12 Months		 (Jun 30 2014)
12 Months
Y / Y Current Liabilities TTM Growth 24.2 % -2.18 % -12.52 % -15.04 % 8.11 %
Y / Y Cash & cash equivalent TTM Growth 17.3 % 21.41 % 28.7 % 88.05 % 97.37 %
Quick Ratio TTM 7.55 7.87 7.68 9.21 7.99
Total Ranking TTM # 400 # 376 # 478 # 290 # 290
Seq. Current Liabilities TTM Growth 13.56 % 8.95 % 4.87 % -4.28 % -10.56 %
Seq. Cash & cash equivalent TTM Growth 8.9 % 11.72 % -12.56 % 10.27 % 12.72 %

Quick ratio ranking by company, industry and sector >> Back to KYTH Financial Strength Comparisons >> Go to Compare KYTH Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2015 to $23.68 millions, cumulative Quick Ratio decreased to 7.55 above the KYTH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 304 other companies have achieved higher Quick Ratio than Kythera Biopharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2015 from 3146 to 3166.

Explain Quick Ratio?
How much Cash & cash equivalents KYTH´s has?
What are KYTH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 305
Healthcare Sector # 629
Within the Market # 404


trailing twelve months Quick Ratio Statistics
High Average Low
5.34 3.88 2.9
(Sep 30 2014)   (Sep 30 2013)




Companies with similar Quick Ratio in the quarter ending Jun 30 2015, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2015 MRQ Cash & cash equivalentJun 30 2015 MRQ Current Liabilities
Amicus Therapeutics inc   21.38 $ 361.419  Millions$ 16.901  Millions
Enanta Pharmaceuticals Inc  21.10 $ 154.286  Millions$ 7.312  Millions
Zs Pharma, Inc.  20.84 $ 234.859  Millions$ 11.270  Millions
Flexion Therapeutics Inc   20.83 $ 127.375  Millions$ 6.115  Millions
Immune Design Corp.  20.80 $ 128.998  Millions$ 6.203  Millions
Tempest Therapeutics Inc   20.48 $ 155.619  Millions$ 7.598  Millions
Sage Therapeutics Inc   20.38 $ 224.234  Millions$ 11.000  Millions
Rocket Pharmaceuticals Inc   19.99 $ 49.012  Millions$ 2.452  Millions
Iveric Bio Inc   19.80 $ 449.040  Millions$ 22.680  Millions
Cormedix Inc   19.36 $ 37.488  Millions$ 1.936  Millions
Pulmatrix Inc   19.22 $ 25.507  Millions$ 1.327  Millions
Larimar Therapeutics Inc   19.04 $ 220.120  Millions$ 11.558  Millions
Innoviva Inc   18.77 $ 229.263  Millions$ 12.214  Millions
Revance Therapeutics Inc   18.66 $ 135.336  Millions$ 7.251  Millions
Kura Oncology Inc   18.43 $ 45.933  Millions$ 2.492  Millions
Calithera Biosciences Inc   18.41 $ 77.701  Millions$ 4.221  Millions
Collegium Pharmaceutical Inc   18.16 $ 112.413  Millions$ 6.190  Millions
Epizyme Inc.  17.92 $ 236.695  Millions$ 13.206  Millions
Eledon Pharmaceuticals Inc   17.90 $ 83.194  Millions$ 4.647  Millions
Albireo Pharma inc   17.60 $ 44.355  Millions$ 2.520  Millions
Aimmune Therapeutics Inc   17.58 $ 58.502  Millions$ 3.327  Millions
Anixa Biosciences Inc   17.34 $ 7.561  Millions$ 0.436  Millions
Alpine Immune Sciences Inc   16.42 $ 100.521  Millions$ 6.123  Millions
Portola Pharmaceuticals inc   16.30 $ 401.507  Millions$ 24.635  Millions
Seres Therapeutics Inc   16.27 $ 91.776  Millions$ 5.641  Millions
Lixte Biotechnology Holdings Inc   16.02 $ 1.251  Millions$ 0.078  Millions
Bio path Holdings inc   16.01 $ 11.080  Millions$ 0.692  Millions
Abeona Therapeutics Inc   15.84 $ 30.410  Millions$ 1.920  Millions
Kalvista Pharmaceuticals Inc   15.69 $ 65.381  Millions$ 4.167  Millions
Karyopharm Therapeutics Inc   15.69 $ 221.186  Millions$ 14.099  Millions

Date modified: 2026-09-08T15:07:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.